IN2014DN11099A - - Google Patents

Info

Publication number
IN2014DN11099A
IN2014DN11099A IN11099DEN2014A IN2014DN11099A IN 2014DN11099 A IN2014DN11099 A IN 2014DN11099A IN 11099DEN2014 A IN11099DEN2014 A IN 11099DEN2014A IN 2014DN11099 A IN2014DN11099 A IN 2014DN11099A
Authority
IN
India
Prior art keywords
liposomal irinotecan
leucovorin
fluorouracil
administered
patient
Prior art date
Application number
Inventor
Eliel Bayever
Navreet Dhindsa
Jonathan Basil Fitzgerald
Peter Laivins
Victor Moyo
Clet Niyikiza
Original Assignee
Merrimack Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48692681&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014DN11099(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merrimack Pharmaceuticals Inc filed Critical Merrimack Pharmaceuticals Inc
Publication of IN2014DN11099A publication Critical patent/IN2014DN11099A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Provided are methods for treating pancreatic cancer in a patient by administering liposomal irinotecan (MM 398) alone or in combination with additional therapeutic agents. In one embodiment the liposomal irinotecan (MM 398) is co administered with 5 fluorouracil and leucovorin.
IN11099DEN2014 2012-06-13 2013-06-12 IN2014DN11099A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261659211P 2012-06-13 2012-06-13
US201361784382P 2013-03-14 2013-03-14
PCT/US2013/045495 WO2013188586A1 (en) 2012-06-13 2013-06-12 Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan

Publications (1)

Publication Number Publication Date
IN2014DN11099A true IN2014DN11099A (en) 2015-09-25

Family

ID=48692681

Family Applications (1)

Application Number Title Priority Date Filing Date
IN11099DEN2014 IN2014DN11099A (en) 2012-06-13 2013-06-12

Country Status (21)

Country Link
US (10) US9452162B2 (en)
EP (3) EP2861210B1 (en)
JP (3) JP6310911B2 (en)
KR (3) KR101997206B1 (en)
CN (2) CN110051631A (en)
AU (3) AU2013202947B2 (en)
BR (1) BR112014031088A8 (en)
CA (1) CA2875824C (en)
DK (2) DK3266456T3 (en)
ES (2) ES2880089T3 (en)
IL (3) IL294886A (en)
IN (1) IN2014DN11099A (en)
MX (1) MX376937B (en)
NZ (1) NZ702469A (en)
PL (2) PL2861210T3 (en)
PT (2) PT3266456T (en)
RU (1) RU2663450C2 (en)
SI (2) SI2861210T1 (en)
TW (3) TWI729492B (en)
WO (1) WO2013188586A1 (en)
ZA (1) ZA201408804B (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2967961T3 (en) 2004-05-03 2024-05-06 Ipsen Biopharm Ltd Liposomes useful in drug administration
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
KR102501566B1 (en) 2014-01-14 2023-02-17 넥타르 테라퓨틱스 Combination-based treatment method
MA39599A (en) 2014-05-14 2016-10-05 Merrimack Pharmaceuticals Inc Dosage and administration anti-egfr therapeutics
JP7113619B2 (en) * 2014-12-09 2022-08-05 イプセン バイオファーム リミティド Treatment of breast cancer with liposomal irinotecan
WO2016168451A1 (en) * 2015-04-14 2016-10-20 Merrimack Pharmaceuticals, Inc. Compositions for improving the pharmacokinetics and therapeutic index of cancer treatment
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
WO2017031442A1 (en) 2015-08-20 2017-02-23 Merrimack Pharmaceuticals, Inc. Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
JP2018528185A (en) 2015-08-21 2018-09-27 イプセン バイオファーム リミティド Method for treating metastatic pancreatic cancer using combination therapy comprising liposomal irinotecan and oxaliplatin
CA2998883A1 (en) 2015-09-16 2017-03-23 Board Of Regents, The University Of Texas System Combination of topoisomerase-i inhibitors with immunotherapy in the treatment of cancer
SG10201912568PA (en) 2015-10-16 2020-02-27 Ipsen Biopharm Ltd Stabilizing camptothecin pharmaceutical compositions
WO2017172678A1 (en) * 2016-03-30 2017-10-05 Merrimack Pharmaceuticals, Inc. Methods for treating cancer using combination therapies comprising an oligoclonal anti-egfr antibody preparation and lipsomal irinotecan
BR112018072988A2 (en) * 2016-05-18 2019-04-09 Ipsen Biopharm Ltd. liposomal irinotecan for use in the treatment of small cell lung cancer
KR20190077441A (en) 2016-11-02 2019-07-03 입센 바이오팜 리미티드 Gastric cancer treatment using combination therapy including liposomal irinotecan, oxaliplatin, 5-fluorouracil (and leucovorin)
US12291570B2 (en) * 2018-10-17 2025-05-06 Biolinerx Ltd. Treatment of metastatic pancreatic adenocarcinoma
EP3911353A1 (en) * 2019-01-17 2021-11-24 BioLineRx Ltd. Specific combination therapy for treatment of pancreatic cancer
WO2020148744A1 (en) * 2019-01-17 2020-07-23 Biolinerx Ltd. Combination therapy for treatment of pancreatic cancer
US11286344B2 (en) 2020-01-10 2022-03-29 Tyndall Formulation Services, LLC Polymer excipients for drug delivery applications
US11857630B2 (en) 2020-01-10 2024-01-02 Tyndall Formulation Services, LLC Formulations of SN-38 with poly(amino acid) block polymers
BR112022013685A2 (en) 2020-01-10 2022-09-06 R Pharm Us Operating Llc COMPOSITIONS OF IXABEPILONE
WO2023056485A1 (en) * 2021-10-03 2023-04-06 Systimmune, Inc. Methods of treating cancer and the pharmaceutical compositions thereof

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2628659A (en) * 1951-01-17 1953-02-17 Charles R Carpenter Convertible furniture article
JPS6019790A (en) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd Novel camptothecin derivative
US5077056A (en) 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
JPH0720857B2 (en) 1988-08-11 1995-03-08 テルモ株式会社 Liposome and its manufacturing method
IL91664A (en) 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5538954A (en) 1994-06-24 1996-07-23 A/S Dumex (Dumex Ltd.) Salts of tetracyclines
US5783568A (en) 1994-06-10 1998-07-21 Sugen, Inc. Methods for treating cancer and other cell proliferative diseases
US5543152A (en) 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5800833A (en) 1995-02-27 1998-09-01 University Of British Columbia Method for loading lipid vesicles
DE19605024A1 (en) 1996-01-31 1997-08-07 Schering Ag New selective taxanes, processes for their preparation and their pharmaceutical use
US5997899A (en) 1996-10-01 1999-12-07 Skyepharma Inc. Method for producing liposomes with increased percent of compound encapsulated
CA2269758C (en) 1996-10-22 2008-01-08 Hermes Biosciences, Inc. Liposome compositions comprising ionizable compounds in stable precipitated form and methods for their preparation
US6210707B1 (en) 1996-11-12 2001-04-03 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof
US6787132B1 (en) 1997-12-04 2004-09-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combined chemo-immunotherapy with liposomal drugs and cytokines
US7244826B1 (en) 1998-04-24 2007-07-17 The Regents Of The University Of California Internalizing ERB2 antibodies
US6726925B1 (en) 1998-06-18 2004-04-27 Duke University Temperature-sensitive liposomal formulation
ES2198970T3 (en) 1998-09-16 2004-02-01 Alza Corporation TOPOISOMERASA INHIBITORS CAUGHT IN LIPOSOMAS.
US7311924B2 (en) 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
WO2000066125A1 (en) 1999-04-29 2000-11-09 Aventis Pharma S.A. Method for treating cancer using camptothecin derivatives and 5-fluorouracil
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US6511676B1 (en) 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
US7025988B2 (en) 2000-02-04 2006-04-11 Lipoxen Technologies Limited Liposomes
US6545010B2 (en) 2000-03-17 2003-04-08 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer
CA2408710C (en) 2000-05-15 2010-01-26 Celgene Corp. Compositions and methods for the treatment of colorectal cancer
AU2001270413A1 (en) 2000-06-30 2002-01-14 Inex Pharmaceuticals Corporation Improved liposomal camptothecins and uses thereof
TWI283575B (en) 2000-10-31 2007-07-11 Eisai Co Ltd Medicinal compositions for concomitant use as anticancer agent
CN1294991C (en) 2001-03-26 2007-01-17 阿尔扎公司 Liposome composition for improved intracellular delivery of therapeutic agent
US7219016B2 (en) 2001-04-20 2007-05-15 Yale University Systems and methods for automated analysis of cells and tissues
WO2003030864A1 (en) 2001-05-29 2003-04-17 Neopharm, Inc. Liposomal formulation of irinotecan
US20050032724A1 (en) 2001-07-23 2005-02-10 Gunther Heinrich Methods for improved treatment of cancer with irinotecan based on mrp1
US20030077833A1 (en) * 2001-09-07 2003-04-24 Queen's University At Kingston Diagnositc methods for determining susceptibility to convulsive conditions
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
ITBO20010610A1 (en) 2001-10-05 2003-04-05 Haworth S P A DEVICE FOR THE CONNECTION OF LEGS TO FURNISHING ELEMENTS, AND FURNISHING ELEMENT INCLUDING SUCH DEVICE
AU2003237864B2 (en) 2002-05-15 2008-12-18 California Pacific Medical Center Delivery of nucleic acid-like compounds
EP2431385A3 (en) 2002-05-31 2012-07-04 Morphotek, Inc. Combination therapy with chlorotoxin
WO2004035032A2 (en) 2002-08-20 2004-04-29 Neopharm, Inc. Pharmaceutical formulations of camptothecine derivatives
RS20050885A (en) 2003-05-30 2008-04-04 Genentech Treatment with anti-vegf antibodies
ES2967961T3 (en) 2004-05-03 2024-05-06 Ipsen Biopharm Ltd Liposomes useful in drug administration
US8658203B2 (en) 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
EP1752150B1 (en) 2004-06-01 2016-08-31 Kabushiki Kaisha Yakult Honsha Irinotecan preparation
AU2005249201A1 (en) * 2004-06-03 2005-12-15 F. Hoffmann-La Roche Ag Treatment with irinotecan (CPT-11) and an EGFR-inhibitor
JP2006248978A (en) 2005-03-10 2006-09-21 Mebiopharm Co Ltd New liposome preparation
TWI375673B (en) 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
EP1951239A2 (en) 2005-10-25 2008-08-06 Celator Pharmaceuticals, Inc. Fixed ratio drug combination treatments for solid tumors
US20080269131A1 (en) * 2005-11-10 2008-10-30 Smithkline Beecham Corporation Inhibitors of Akt Activity
US20090148506A1 (en) * 2005-12-22 2009-06-11 Awa Dicko Liposomal formulations comprising secondary and tertiary amines and methods for preparing thereof
EP2329818A1 (en) 2006-01-17 2011-06-08 Abbott Laboratories Combination therapy with PARP inhibitors
CA2647297A1 (en) 2006-03-16 2007-09-27 Bionumerik Pharmaceuticals, Inc. Anti-cancer activity augmentation compounds and formulations and methods of use thereof
KR101107911B1 (en) * 2006-11-30 2012-01-25 아크레이 가부시키가이샤 Primer set for amplification of ugt1a1 gene, reagent for amplification of ugt1a1 gene comprising the same, and use of the same
HRP20131113T1 (en) 2007-02-16 2014-01-17 Merrimack Pharmaceuticals, Inc. Antibodies against erbb3 and uses thereof
US20120003160A1 (en) 2007-06-29 2012-01-05 Amag Pharmaceuticals, Inc. Macrophage-Enhanced MRI (MEMRI) in a Single Imaging Session
EP2187869B1 (en) 2007-08-17 2015-10-14 Celator Pharmaceuticals, Inc. Improved platinum drug formulations
AU2008303466A1 (en) * 2007-09-28 2009-04-02 Universitatsspital Basel Immunoliposomes for treatment of cancer
WO2009064444A2 (en) 2007-11-12 2009-05-22 Bipar Sciences, Inc. Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents
CA2708157A1 (en) 2007-12-07 2009-06-11 Bipar Sciences, Inc. Treatment of cancer with combinations of topoisomerase inhibitors and parp inhibitors
TWI444384B (en) * 2008-02-20 2014-07-11 Gilead Sciences Inc Nucleotide analogues and their use in the treatment of malignancies
CA2718918A1 (en) 2008-03-25 2009-11-26 Schering Corporation Methods for treating or preventing colorectal cancer
US8067432B2 (en) 2008-03-31 2011-11-29 University Of Kentucky Research Foundation Liposomal, ring-opened camptothecins with prolonged, site-specific delivery of active drug to solid tumors
CN102057054B (en) 2008-04-11 2015-06-10 梅里麦克制药股份有限公司 Human serum albumin linkers and conjugates thereof
US8852630B2 (en) 2008-05-13 2014-10-07 Yale University Chimeric small molecules for the recruitment of antibodies to cancer cells
CA2738755C (en) * 2008-09-26 2018-11-06 Universite D'angers Individual 5-fluorouracile dose optimization in folfiri treatment
US8927694B2 (en) 2008-11-18 2015-01-06 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
JP2012525371A (en) 2009-05-01 2012-10-22 オンコザイム・ファーマ・インコーポレイテッド Pentamidine combination to treat cancer
DK2508170T3 (en) 2009-12-03 2015-09-21 Jiangsu Hengrui Medicine Co LIPOSOM OF IRINOTECAN OR ITS HYDROCHLORIDE AND ITS PROCEDURE
WO2011153010A1 (en) 2010-06-04 2011-12-08 Abraxis Biosciences, Llc Methods of treatment of pancreatic cancer
WO2012012454A1 (en) 2010-07-19 2012-01-26 Bipar Sciences, Inc. Methods of treating metastatic breast cancer with 4-iodo-3-nitrobenzamide and irinotecan
CN103168104B (en) 2010-07-22 2016-09-28 加利福尼亚大学董事会 Anti-tumor antigen antibodies and methods of use thereof
WO2012031293A1 (en) 2010-09-03 2012-03-08 Board Of Regents Of The University Of Nebraska Compositions and methods for the treatment of cancer
KR20140041396A (en) 2010-12-06 2014-04-04 메리맥 파마슈티컬즈, 인크. Dosage and administration for preventing cardiotoxicity in treatment with erbb2-targeted immunoliposomes comprising anthracyclin chemotherapeutic agents
AU2011344865B2 (en) 2010-12-14 2017-03-09 Rigshospitalet Entrapment of radionuclides in nanoparticle compositions
EP2675918B1 (en) 2011-02-15 2017-11-08 Merrimack Pharmaceuticals, Inc. Compositions and methods for delivering nucleic acid to a cell
DK2699602T3 (en) 2011-04-19 2017-06-06 Merrimack Pharmaceuticals Inc BISPECIFIC ANTI-IGF-1R AND ANTI-ERBB3 ANTIBODIES
JO3283B1 (en) * 2011-04-26 2018-09-16 Sanofi Sa Composition including Afflipersept, Folinic Acid, 5- Fluorouracil (5- Fu) and Irenosetan (FOLFIRI)
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
AU2013201584A1 (en) * 2012-03-12 2013-09-26 Merrimack Pharmaceuticals, Inc. Methods for treating pancreatic cancer using combination therapies comprising an anti-ErbB3 antibody
AU2013249307B2 (en) 2012-04-17 2017-11-09 Merrimack Pharmaceuticals, Inc. Compositions and methods for non-invasive imaging
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2013374248A1 (en) 2012-12-14 2015-06-11 Merrimack Pharmaceuticals, Inc. Non-invasive imaging methods for patient selection for treatment with nanoparticulate therapeutic agents
SI2979700T1 (en) 2013-03-27 2019-01-31 Taiho Pharmaceutical Co., Ltd. Antitumor agent including low dose irinotecan hydrochloride hydrate
JP2016529284A (en) 2013-08-27 2016-09-23 ノースイースタン ユニバーシティ Nanoparticle drug delivery system and method for treating cancer and neurotrauma
WO2015061592A1 (en) 2013-10-23 2015-04-30 Merrimack Pharmaceuticals, Inc. Liposomes for non-invasive imaging and drug delivery
JP7113619B2 (en) 2014-12-09 2022-08-05 イプセン バイオファーム リミティド Treatment of breast cancer with liposomal irinotecan
WO2016168451A1 (en) 2015-04-14 2016-10-20 Merrimack Pharmaceuticals, Inc. Compositions for improving the pharmacokinetics and therapeutic index of cancer treatment
WO2017031442A1 (en) 2015-08-20 2017-02-23 Merrimack Pharmaceuticals, Inc. Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
JP2018528185A (en) 2015-08-21 2018-09-27 イプセン バイオファーム リミティド Method for treating metastatic pancreatic cancer using combination therapy comprising liposomal irinotecan and oxaliplatin
SG10201912568PA (en) 2015-10-16 2020-02-27 Ipsen Biopharm Ltd Stabilizing camptothecin pharmaceutical compositions
US20170202840A1 (en) 2016-01-14 2017-07-20 Merrimack Pharmaceuticals, Inc. Treatment of pancreatic cancer with liposomal irinotecan
WO2017172678A1 (en) 2016-03-30 2017-10-05 Merrimack Pharmaceuticals, Inc. Methods for treating cancer using combination therapies comprising an oligoclonal anti-egfr antibody preparation and lipsomal irinotecan
BR112018072988A2 (en) 2016-05-18 2019-04-09 Ipsen Biopharm Ltd. liposomal irinotecan for use in the treatment of small cell lung cancer
US20170333421A1 (en) 2016-05-18 2017-11-23 Ipsen Biopharm Ltd. Population Pharmacokinetics of Liposomal Irinotecan
KR20190077441A (en) 2016-11-02 2019-07-03 입센 바이오팜 리미티드 Gastric cancer treatment using combination therapy including liposomal irinotecan, oxaliplatin, 5-fluorouracil (and leucovorin)

Also Published As

Publication number Publication date
DK3266456T3 (en) 2021-07-05
HK1248608A1 (en) 2018-10-19
KR20150021565A (en) 2015-03-02
KR20170104638A (en) 2017-09-15
EP3919048A1 (en) 2021-12-08
PL2861210T3 (en) 2017-12-29
BR112014031088A2 (en) 2017-06-27
RU2015100529A (en) 2016-08-10
IL235937B (en) 2022-08-01
TW201412345A (en) 2014-04-01
DK2861210T3 (en) 2017-07-24
US9364473B2 (en) 2016-06-14
AU2013202947B2 (en) 2016-06-02
US9492442B2 (en) 2016-11-15
AU2018201942A1 (en) 2018-04-12
JP2019116517A (en) 2019-07-18
KR101997206B1 (en) 2019-07-08
US20240226090A1 (en) 2024-07-11
BR112014031088A8 (en) 2021-06-22
SI2861210T1 (en) 2017-10-30
ES2632915T3 (en) 2017-09-18
US20160074382A1 (en) 2016-03-17
US20220096458A1 (en) 2022-03-31
JP2015523355A (en) 2015-08-13
KR101776808B1 (en) 2017-09-11
TW201831168A (en) 2018-09-01
US20170368056A1 (en) 2017-12-28
US20170065578A1 (en) 2017-03-09
IL235937A0 (en) 2015-01-29
JP6857210B2 (en) 2021-04-14
US20150182521A1 (en) 2015-07-02
MX2014015391A (en) 2015-06-17
IL304631A (en) 2023-09-01
MX376937B (en) 2025-03-07
US9339497B2 (en) 2016-05-17
ES2880089T3 (en) 2021-11-23
PT2861210T (en) 2017-07-26
US20160228428A1 (en) 2016-08-11
RU2018126616A (en) 2019-03-12
CA2875824A1 (en) 2013-12-19
US10980795B2 (en) 2021-04-20
EP2861210A1 (en) 2015-04-22
CA2875824C (en) 2021-05-18
AU2013274287A1 (en) 2015-01-29
CN110051631A (en) 2019-07-26
US9452162B2 (en) 2016-09-27
JP2017149783A (en) 2017-08-31
AU2018201942B2 (en) 2019-12-05
TWI729492B (en) 2021-06-01
AU2013274287B2 (en) 2017-12-21
TWI630924B (en) 2018-08-01
CN104717961A (en) 2015-06-17
WO2013188586A1 (en) 2013-12-19
TW202027727A (en) 2020-08-01
KR20190107010A (en) 2019-09-18
US20150328156A1 (en) 2015-11-19
SI3266456T1 (en) 2022-03-31
HK1209627A1 (en) 2016-04-08
EP2861210B1 (en) 2017-05-03
NZ702469A (en) 2017-08-25
ZA201408804B (en) 2017-06-28
US20190117643A1 (en) 2019-04-25
EP3266456B1 (en) 2021-05-05
EP3266456A1 (en) 2018-01-10
PT3266456T (en) 2021-07-28
US20150374682A1 (en) 2015-12-31
PL3266456T3 (en) 2021-11-29
RU2663450C2 (en) 2018-08-06
JP6310911B2 (en) 2018-04-11
AU2013202947A1 (en) 2014-01-16
IL294886A (en) 2022-09-01

Similar Documents

Publication Publication Date Title
IN2014DN11099A (en)
NZ630805A (en) Pharmaceutical combinations comprising a thionucleotide analog
MX2017014338A (en) Targeted selection of patients for treatment with cortistatin derivatives.
PH12017501500A1 (en) Methods for treating non- small cell lung cancer using tor kinase inhibitor combination therapy
NZ631144A (en) Compositions and methods for transmucosal absorption
MY189466A (en) Methods of modulating drug plasma levels using erythrohydroxybupropion
NZ711373A (en) Fragments of p97 and uses thereof
MY204500A (en) Dosing regimen associated with long acting injectable paliperidone esters
GB201111485D0 (en) Drug composition and its use in therapy
MX2020012924A (en) Treatment of cancer using coenzyme q10 combination therapies.
PH12014502738A1 (en) High-xten fusion protein and its use in the treatment of growth hormone deficiency
PH12014500386A1 (en) Combination treatment for hepatitis c
IN2015DN03219A (en)
SG195110A1 (en) Pirfenidone and anti-fibrotic therapy in selected patients
MX2015010791A (en) Methods of treating cancer and preventing drug resistance.
PH12015502616A1 (en) Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer
HK1201462A1 (en) Methods of treating cancer
PH12014500381A1 (en) Therapeutic methods
WO2013096335A8 (en) ADMINISTRATION OF AN ANTAGONIST OF α5β1 FOR ANTI-ANTIOGENESIS AND CANCER TREATMENT
NZ594414A (en) Fused amino pyridines for the treatment of brain tumors
EP2836217A4 (en) Compositions and methods for treatment of the side-effects associated with administration of cancer chemotherapeutic agents
HK1200731A1 (en) Diethyl- [6- (4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl) - naphthalen-2-yl-methyl] -ammonium chloride for use in the treatment of muscular dystrophy
TN2014000418A1 (en) Methods for treating cancer using pi3k inhibitor and mek inhibitor
MX2014013491A (en) Methods of maintaining, treating or improving cognitive function.
UA88769U (en) Method for preventing and treating benign breast dysplasia in patients with early miscarriage